StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > House Positions for C:SZLS.WT from 20201220 to 20210120

<< Previous

Bullboard Posts

Next >>

Comment by Amir97on Jan 22, 2021 3:01am

164 Views

Post# 32357023

RE:House Positions for C:SZLS.WT from 20201220 to 20210120

I hope all goes well with this one!! This is amazing, especially if it gets to deliver its functions well. It is really great if we can detect cancer in its early stages. Hopefully, this can be done before complications start to occur. Prevention is better than cure so I really think that detecting diseases is really better than undergoing treatments. Goodluck to this company.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide